No profile data available.
Bicycle Therapeutics plc (BCYC) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Cambridge, United Kingdom, with about 288 full-time employees.
It reported revenue of $72.59 million for fiscal year 2025, up 105.8% from fiscal year 2024, and net income of -$218.96 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $629,000, down 78.5% from a year before. Its market capitalization was $271.57 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
Bicycle Therapeutics reported $72.59 million in revenue for fiscal year 2025, up 105.8% from $35.28 million in fiscal year 2024. In Q2 2026 revenue was $629,000.
$271.57 million as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Silence Therapeutics plc (SLN), Contineum Therapeutics, Inc. (CTNM), Probi AB (publ) (PBBIF), Protara Therapeutics, Inc. (TARA).